← Back to Home

Enhertu gains EU approval for adjuvant treatment of residual breast cancer after preoperative therapy

For patients with HER2-positive early breast cancer, reducing the risk of recurrence after surgery is a key step in treatment. Enhertu has secured a new EU indication based on phase 3 results showing superiority to T-DM1, but pulmonary toxicity and long-term survival benefits still require careful consideration.

By SURL BioNews

When invasive cancer cells remain in surgical specimens after preoperative drug treatment for breast cancer, the risk of subsequent recurrence remains. On October 27, the European Commission approved Enhertu (trastuzumab deruxtecan, T-DXd) for postoperative adjuvant treatment of these patients with HER2-positive early breast cancer, adding an option to reduce the risk of recurrence. This is also the drug’s first EU indication for early breast cancer with curative intent.

According to announcements from AstraZeneca and Daiichi Sankyo, the approval covers adult patients who have undergone surgery: their tumors must be HER2-positive, with residual invasive disease after preoperative treatment containing a taxane and HER2-targeted therapy. Enhertu is used as monotherapy in this setting, which applies to a specific treatment stage and pathological criteria, rather than to all patients with early breast cancer.

DESTINY-Breast05, which supported the approval, is a randomized, open-label phase 3 trial enrolling 1,635 participants, all of whom had residual disease and a higher risk of recurrence. The study compared Enhertu with the existing standard treatment, T-DM1, with both groups receiving intravenous treatment once every three weeks for a planned 14 cycles. Both are antibody-drug conjugates (ADCs), which use an antibody that recognizes HER2 to deliver a cytotoxic drug; Enhertu carries a topoisomerase I inhibitor.

In the trial, 51 of the 818 participants in the Enhertu group experienced invasive disease recurrence or death, compared with 102 of the 817 participants in the T-DM1 group. Three-year invasive disease-free survival rates were 92.4% and 83.7%, respectively, a difference of 8.7 percentage points. The hazard ratio was 0.47, representing a 53% reduction in the relative risk of an event during follow-up. This figure describes the composite endpoint of recurrence or death and cannot be directly interpreted as a halving of the risk of death.

For another secondary endpoint, disease-free survival, the three-year rates were 92.3% versus 83.5%, differing slightly from the primary endpoint because of differences in definition. As for whether overall survival can be extended, deaths remained few at this interim analysis, and the evidence was not yet sufficient to confirm a benefit. Efficacy also comes at a cost: the incidence of interstitial lung disease adjudicated as drug-related was 9.6% in the Enhertu group, higher than the 1.6% in the T-DM1 group. Most cases were mild to moderate, but fatal cases also occurred in the Enhertu group. This risk particularly needs to be considered in treatment assessments for patients with early disease who may survive for many years.

Background

Research in early breast cancer is exploring two paths simultaneously: reducing the burden of conventional chemotherapy for some patients and increasing the intensity of anticancer treatment for those with residual disease after treatment. This approval falls into the latter category and is based on a large trial directly comparing the drug with an existing therapy. It translates evidence of reduced recurrence risk into an approved use in the EU. How much long-term survival can improve, and when patients in different locations will actually gain access to treatment, remain questions for further follow-up and national reimbursement arrangements to answer.

References

  1. AstraZeneca
  2. Daiichi Sankyo via Business Wire / BioSpace
  3. OncLive